ArticleClinical lymphoma, myeloma & leukemia2023

Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.

Muhamad Alhaj Moustafa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.